Albinterferon Alfa-2B
- Generic Name
- Albinterferon Alfa-2B
- Drug Type
- Biotech
- CAS Number
- 472960-22-8
- Unique Ingredient Identifier
- 4DVS4AG4DF
- Background
Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.
- Indication
Investigated for use/treatment in hepatitis (viral, C).
Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2011-01-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 141
- Registration Number
- NCT00964665
- Locations
- 🇹🇭
Novartis Investigator Site, Songkla, Thailand
An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals
- Conditions
- HCVHIV Infections
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 41
- Registration Number
- NCT00489385
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.